Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 338 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | August 15, 2014

Why Achillion Pharmaceuticals, Inc. Stock Soared

Achillion stock is among the top gainers as its experimental hepatitis C combination therapy delivers "perfect" results.

Investing | July 19, 2014

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.

Investing | July 16, 2014

Will Incoming Competition Derail Aegerion Stock?

A new class of cholesterol drugs including Amgen's (AMGN) evolocumab could soon be competing for Aegerion's (AEGR) market share in HoFH patients.

Investing | July 15, 2014

Why Is Wall Street Bullish on These 3 Stocks?

Wall Street has been buying AbbVie, Allergan, and Pfizer and short-sellers have stayed away from these stocks. Here's why.

Investing | July 12, 2014

This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something

Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.

Investing | July 05, 2014

This Week in Biotech: Allergan Three-Peats in a Bad Way While Agenus Impresses

An early FDA approval, an inhaled therapy being turned away by regulators for a third time, and three positive clinical updates are this week's top biotech stories.

Investing | June 28, 2014

This Week in Biotech: MannKind's "Finally" Moment and Vertex's Breathtaking Data

MannKind receives favorable news from the FDA while Vertex stuns investors. Plus, three additional biotech companies deliver encouraging clinical results.

Investing | June 24, 2014

Takeover Tango: Healthcare's Best Dance Partner Is...

AbbVie and Shire. Valeant and Allergan. The drugmaker deal dances are underway -- but it takes two to tango.

Investing | May 16, 2014

Better Buy: Isis vs. Aegerion

Which drug -- and which stock -- is better?

Investing | May 12, 2014

Monday’s Top Health Care Stories: Tesaro, Alnylam, Allergan, and Valeant

Tesaro, Alnylam, Allergan, and Valeant could make waves across the health-care sector this morning.

Results 1 - 10 of 338 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology